Maeda, H., Edo, K., and Ishida, N., Eds. (1997) Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug, pp1−289,Springer-Verlag,Tokyo.
Maeda H., 1997, Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug, 227, 10.1007/978-4-431-66914-2_12
Maeda H., 1985, J. Med. Chem., 28, 455, 10.1021/jm00382a012
Kobayashi A., 1988, J. Bioact. Compat. Polym., 3, 319, 10.1177/088391158800300401
Matsumoto K., 1984, J. Biochem., 96, 739, 10.1093/oxfordjournals.jbchem.a134892
Molla A., 1989, J. Biol. Chem., 264, 10589, 10.1016/S0021-9258(18)81661-1
Maeda H., 1996, Microbiol. Immunol., 40, 685, 10.1111/j.1348-0421.1996.tb01129.x
Maeda H., 2002, Wiley Encyclopedia of Molecular Medicine, 4, 2663
Maeda H., 1993, Proteases, Proteases Inhibitor and Protease-Derived Peptides: Importance in Human Pathophysiology and Therapeutics. Agents Actions Supplement, 42, 159, 10.1007/978-3-0348-7397-0_13
Maeda H., 1988, J. Biol. Chem., 263, 16051, 10.1016/S0021-9258(18)37555-0
Matsumura Y., 1986, Cancer Res., 46, 6387
Matsumura Y., 1988, Jpn. J. Cancer Res., 79, 1327, 10.1111/j.1349-7006.1988.tb01563.x
Matsumura Y., 1991, Jpn. J. Cancer Res., 82, 732, 10.1111/j.1349-7006.1991.tb01910.x
Wu J., 1998, Cancer Res., 58, 159
Maeda H., 1999, Immunopharmacology, 43, 115, 10.1016/S0162-3109(99)00104-6
Maeda H., 1991, Adv. Drug Delivery Rev., 6, 181, 10.1016/0169-409X(91)90040-J
Iwai K., 1984, Cancer Res., 44, 2115
Konno T., 1984, Cancer, 54, 2367, 10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F
Maki S., 1985, Cancer, 56, 751, 10.1002/1097-0142(19850815)56:4<751::AID-CNCR2820560409>3.0.CO;2-Y
Nagamitsu A., 2009, Jpn. J. Clin. Oncol., 39, 756, 10.1093/jjco/hyp074
Folkman J., 1974, Adv. Cancer Res., 19, 331, 10.1016/S0065-230X(08)60058-5
Skinner S. A., 1990, Cancer Res., 50, 2411
Greish K., 2005, Bioconjugate Chem., 16, 230, 10.1021/bc040297g
Maeda H., 1992, Bioconjugate Chem., 3, 351, 10.1021/bc00017a001
Yokoyama M., 1994, J. Controlled Release, 32, 269, 10.1016/0168-3659(94)90237-2
Duncan R., 2009, Adv. Drug Delivery Rev., 61, 1131, 10.1016/j.addr.2009.05.007
Iyer A., 2007, J. Drug Targeting, 15, 496, 10.1080/10611860701498252
Zalipsky S., 2007, J. Drug Targeting, 15, 518, 10.1080/10611860701499946
Fang J., 2007, J. Drug Targeting, 15, 475, 10.1080/10611860701498286
Kimura N. T., 1980, Cancer Res., 96, 739
Zhao M., 2006, Cancer Res., 66, 7647, 10.1158/0008-5472.CAN-06-0716
Torchilin V., 2010, Adv. Drug Delivery Rev.
Maeda H., 1994, Jpn. J. Cancer Res., 85, 331, 10.1111/j.1349-7006.1994.tb02362.x
Wu J., 2001, Jpn. J. Cancer Res., 92, 439, 10.1111/j.1349-7006.2001.tb01114.x
Tanaka S., 2003, J. Drug Targeting, 11, 45, 10.1080/1061186031000086072
Maeda H., 2001, Adv. Enzyme Regul., 41, 189, 10.1016/S0065-2571(00)00013-3
Suzuki M., 1981, J. Natl. Cancer Inst., 67, 663
Li C. J., 1993, Br. J. Cancer, 67, 975, 10.1038/bjc.1993.179
Maeda, H., Seki, T., and Fang, J. (2008) Enhanced tumor delivery of macromolecular antitumor-drugs by topical application of nitroglycerin on superficial tumors,Abstract #P-518 in the 67th Annual Meeting of the Japanese Cancer Association,Nagoya, p213.
Seki T., 2009, Cancer Sci., 100, 2426, 10.1111/j.1349-7006.2009.01323.x
Feelisch M., 1987, Eur. J. Pharmacol., 139, 19, 10.1016/0014-2999(87)90493-6
Yasuda H., 2006, J. Clin. Oncol., 24, 688, 10.1200/JCO.2005.04.0436
Yasuda H., 2006, Clin. Cancer Res., 12, 6748, 10.1158/1078-0432.CCR-06-1124
Siemens D. R., 2009, Urology, 74, 878, 10.1016/j.urology.2009.03.004
Maeda H., 2009, Eur. J. Pharm. Biopharm., 71, 409, 10.1016/j.ejpb.2008.11.010
Daruwalla J., 2009, J. Vasc. Res., 46, 218, 10.1159/000165380
Maeda H., 1986, Protein Tailoring for Food and Medical Uses, 353
